Q4 Earnings Forecast for CalciMedica Issued By HC Wainwright

CalciMedica, Inc. (NASDAQ:CALC) – Investment analysts at HC Wainwright issued their Q4 2025 EPS estimates for CalciMedica in a research note issued to investors on Tuesday, April 1st. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($0.48) for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($2.21) per share.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.14.

CalciMedica Price Performance

CALC opened at $1.95 on Wednesday. The firm has a market cap of $26.29 million, a PE ratio of -1.81 and a beta of 1.20. The stock has a 50-day moving average price of $2.34 and a 200-day moving average price of $3.11. CalciMedica has a 1 year low of $1.81 and a 1 year high of $6.27.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. PVG Asset Management Corp bought a new stake in shares of CalciMedica during the third quarter valued at approximately $67,000. Cetera Investment Advisers increased its holdings in shares of CalciMedica by 37.1% in the 4th quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after purchasing an additional 4,566 shares in the last quarter. Wealthedge Investment Advisors LLC purchased a new position in shares of CalciMedica in the fourth quarter worth $98,000. Atria Investments Inc lifted its holdings in shares of CalciMedica by 28.3% during the fourth quarter. Atria Investments Inc now owns 34,012 shares of the company’s stock valued at $120,000 after purchasing an additional 7,509 shares in the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in shares of CalciMedica during the fourth quarter valued at $135,000.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.